CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Open accessThe DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.
Abstract
CTL-associated antigen 4 (CTLA4) blockade releases inhibitory controls on T cell activation and proliferation, inducing antitumor immunity in both preclinical and early clinical trials. We examined the mechanisms of action of anti-CTLA4 and a GM-CSF-transduced tumor cell vaccine (Gvax) and their impact on the balance of effector T cells (Teffs) and Tregs in an in vivo model of B16/BL6 melanoma. Tumor challenge increased the frequency of Tregs in lymph nodes, and untreated tumors became infiltrated by CD4+Foxp3- and CD4+Foxp3+ T cells but few CD8+ T cells. Anti-CTLA4 did not deplete Tregs or permanently impair their function but acted in a cell-intrinsic manner on both Tregs and Teffs, allowing them to expand, most likely in response to self antigen. While Gvax primed the tumor-reactive Teff compartment, inducing activation, tumor infiltration, and a delay in tumor growth, the combination with CTLA4 blockade induced greater infiltration and a striking change in the intratumor balance of Tregs and Teffs that directly correlated with tumor rejection. The data suggest that Tregs control both CD4+ and CD8+ T cell activity within the tumor, highlight the importance of the intratumor ratio of effectors to regulators, and demonstrate inversion of the ratio and correlation with tumor rejection during Gvax/anti-CTLA4 immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Quezada et al., 2006
Experimental — accuracy not yet measuredIn the citing paper
“Mouse melanoma models, for example, have shown that the combination of anti-CTLA-4 with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or with agonistic antibodies targeting costimulatory receptors such as CD40, increased tumor rejection in a synergistic manner (121, 122).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [121]
In the citing paper
“In general, anti-CTLA4 expands CD4 effector T cells (Teff) with subsequent increase in the Teff/ Treg ratio in responding tumors (22).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 601–697 of 697
Immune Environment of Cutaneous Malignancies
Ovits, C., & Carucci, J. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-29785-9_42 · Cited by 1
Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy
Maniyar, R. R., Chakraborty, S., Jarboe, T., Suriano, R., Wallack, M. K., Geliebter, J., & Tiwari, R. K. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-83282-7_6 · Cited by 1
Treg, Chemokines, and Other Small Molecules: Role in Metastasis and Its Prevention
Oble, D. A., Hodi, F. S., Lauwers, G. Y., Dranoff, G., & Mihm, M. C. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-087-8_24 · Cited by 1
Engulfing tumors with synthetic extracellular matrices for cancer
Hori, Y., Stern, P., Hynes, R. O., & Irvine, D. J. (2009) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 1
Highlights from the perspectives in melanoma XII conference
Kirkwood, J. M., & Eggermont, A. M. M. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00555.x · Cited by 1
“Another recent study reported that combining antibodies to cytotoxic T-lymphocyte antigen-4 (CTLA-4) with GM–CSF vaccination enhanced elimination of tumors in a mouse melanoma model by improving the balance of effector to regulatory T cells (Quezada et al., 2006).”
BackgroundTransplantable Syngeneic Murine Tumor Models
Woessner, R., Borodovsky, A., Sachsenmeier, K. F., Scheuplein, F., Wilkinson, R. W., Ye, C., & Dovedi, S. J. (2022) · Wiley eBooks · doi:10.1002/9781119535331.ch1 · Cited by 1
Tracking antigen-specific T cell response to cancer immunotherapyPreprint
Shagina, I. A., Nakonechanaya, T. O., Izosimova, A. V., Yuzhakova, D. V., Skatova, V. D., Lupyr, K. R., Izraelson, M., Davydov, A. N., Shugay, M., Britanova, O. V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.29.626027 · Cited by 1
Quality of CTL Therapies: A Changing Landscape
Thyagarajan, K., Chatterjee, S., Kesarwani, P., Nishimura, M. I., & Mehrotra, S. (2015) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-17807-3_14
“Further studies by this group showed that blockade of CTLA-4 in combination with a GM-CSF-transduced vaccine could eradicate poorly immunogenic tumors by enhancing the effi cacy of tumor-reactive T cells and altering the intratumor balance of effector and regulatory T cells [ 178 ].”
BackgroundCoca, R. C. (2011) · Institutional Repository of the University of Granada (University of Granada)
The tumour microenvironment influences antigen specific T cell transmigration
Popple, A. L. (2012) · Nottingham ePrints (University of Nottingham) · Cited by 1
Materials to Engineer the Immune System
Mooney, D. J. (2010)
L’abatacept dans la polyarthrite rhumatoïde
Falgarone, G., Dumont‐Fischer, D., & Saidenberg-Kermanac’h, N. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0124-7_6
In Vivo Induction of T-Follicular Helper Cells by Modulation of Regulatory T Cell Function
Wing, J. B., & Sakaguchi, S. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2498-1_7
Targeting Cancer Associated Fibroblasts for Cancer Immunotherapy
(2014) · Cancer Cell & Microenvironment · doi:10.14800/ccm.80
“CTLA4 blockade or activating GITR (glucocorticoidinduced TNFR) can overcome Treg-mediated suppression by overactivating cytotoxic T lymphocytes (CTL) and Thelpers (Th) ([17-21]).”
BackgroundStudies on the immune system in CLL
Mous, R. (2008) · UvA-DARE (University of Amsterdam)
Ipilimumab: report and comment about the MDX010-020 clinical trial
Nicoletti, S. V. L., Rosa, F. D., & Ridolfi, R. (2012) · Expert Review of Dermatology · doi:10.1586/edm.12.53
Hepatitis B and the Immune System
Chang, K. (2010) · Current Hepatology Reports · doi:10.1007/s11901-010-0051-5
“Despite some difficulties in identifying “true” Tregs, efforts are ongoing to examine a therapeutic role for Treg induction or suppression [61].”
BackgroundAnti-CTLA-4 Monoclonal Antibodies
Yang, A. S., & Wolchok, J. D. (2011) · Springer eBooks · doi:10.1007/978-1-61779-407-0_14
Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2007)
Cancer Immunology, Immunotherapeutics, and Vaccine Approaches
Madan, R. A., Gulley, J. L., Celestin, J., Arlen, P. M., & Schlom, J. (2010) · Springer eBooks · doi:10.1007/978-1-60327-829-4_27
“A recent study showed that anti-CTLA-4 monotherapy proportionally increased Tregs and effector T cells (Teffs) within the tumor, whereas CTLA-4 blockade with vaccine increased Teffs more than Tregs and, unlike CTLA-4 blockade alone, induced tumor rejection [ 52 ].”
BackgroundVasievich, E. A. (2011) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/jsg4-4558
Glucocorticoid-Induced TNF Receptor (GITR)
Wolchok, J. D., Cohen, A. D., & Schaer, D. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_6-2
Simpson, T. R., & Allison, J. P. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_140
Vaccines and Their Role in CD8 T Cell-Mediated Antitumor Immunity
Kinkead, H. L., Jaffee, E. M., Lutz, E. R., & Armstrong, T. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17019-5
Bergerhoff, K. F. (2016) · UCL Discovery (University College London)
Bot, A. I., & Obrocea, M. (2008) · Translational medicine series · doi:10.3109/9781420054682.008
нОвЫе ПО дхОдЫ К ПОвЫшенИю эффеК тИвнОстИ ПРОтИв ООПУхОлев ОгО ИММУннОг О Ответ А
Григорьевна, К. З., & Ивановна, Ч. А. (2015) · Immunologiya
Superiority of ear skin for DNA immunization in mouse tumor models
Ni, J. (2008) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00008682
Bartkowiak, T. (2017) · Digital Commons-TMC (Texas Medical Center)
CTLA-4 inhibitors in castration-resistant prostate cancer
Subudhi, S. K., Scher, H. I., & Allison, J. P. (2011) · doi:10.2217/ebo.11.345
Introduction to Melanoma Immunology
Sullivan, R. J., & Hodi, F. S. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_36-1
Wang, Y. (2014) · doi:10.18130/v36n8r
“Tumor cells have also been found to secrete immunosuppressive cytokines such as transforming growth factor β (TGF-β) and interleukin 10 (IL-10) (Quezada et al. 2006).”
BackgroundMelanoma Immunology and Immunotherapy
Sullivan, R. J., & Hodi, F. S. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_36-2
Defining and targeting combination immunotherapies in mouse models of cancer
Demane, F., & Demane, D. F. (2019) · UCL Discovery (University College London)
Anticancer Immunotherapy: Prospects and Challenges
Sachdeva, R., Singh, P., Bose, A., Kalha, B., Sarkar, M., & Pal, R. (2019) · Springer eBooks · doi:10.1007/978-981-32-9816-3_8
Wei, B.-L. Z.-Q., & Italia, S.-V. (2015)
Cancer immunotherapy targeting T cell costimulatory molecules
Pardee, A. D. (2010) · D-Scholarship@Pitt (University of Pittsburgh)
Pineda, F. N., & de Jesús, M. (2000) · Investigación Universitaria Multidisciplinaria: Revista de Investigación de la Universidad Simón Bolívar
Management of Metastatic Bladder Tumours
Galsky, M. D. (2014) · Springer eBooks · doi:10.1007/978-0-85729-482-1_36
Checkpoint Blockade and Combinatorial Immunotherapies
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_16
“In addition, anti-CTLA-4 does not successfully reverse in vitro suppression in all studies, which suggest that CTLA-4 blockade has only a moderate or no effect on the suppressive function of CD4+CD25+ regulatory T cells [109–112].”
BackgroundSharma, P., Subudhi, S. K., Peggs, K. S., Goswami, S., Gao, J., Quezada, S. A., & Allison, J. P. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm068
Simpson, T. R., & Allison, J. P. (2015) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_140-1
Lambe, T., & Cornall, R. J. (2008) · Experimental Dermatology · doi:10.1111/j.1600-0625.2007.00666_12.x
Glucocorticoid-Induced TNF Receptor (GITR)
Wolchok, J. D., Cohen, A. D., & Schaer, D. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_6
Palma, G. (2017) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101719-1
Hughes, T., & Kaufman, H. L. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_59-4
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
Myers, J. W., Peoples, G. E., & Clifton, G. T. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_6 · Cited by 1
Eisenlohr, L. C., & Cosma, G. L. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726981821.793545053
Melanoma Immunology and Immunotherapy
Sullivan, R. J., & Hodi, F. S. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7147-9_36
Leonard, W. J., & Spolski, R. J. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727509038.793537551
Li, X. C. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717957676.793462081
Hughes, T. M., & Kaufman, H. L. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_59
Palma, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101719
Biomarkers predicting the effect of immunotherapy: what you need to know in practice?
Konstantinova, A. M. (2022) · Practical oncology · doi:10.31917/2302081 · Cited by 1
Mitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., Kondo, S., Allison, J. P., Sakaguchi, S., Old, L. J., et al. (2023) · doi:10.1158/1078-0432.c.6519084.v1
Kim, H. S., Kim‐Schulze, S., Kim, D., & Kaufman, H. L. (2023) · doi:10.1158/0008-5472.c.6500054.v1
Pardee, A. D., McCurry, D., Alber, S. M., Hu, P., Epstein, A. L., & Storkus, W. J. (2023) · doi:10.1158/0008-5472.c.6500745
Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Gnjatic, S., Altorki, N. K., Tang, D. N., Tu, S., Kundra, V., Ritter, G., Old, L. J., Logothetis, C. J., & Sharma, P. (2023) · doi:10.1158/1078-0432.c.6517543
Mitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., Kondo, S., Allison, J. P., Sakaguchi, S., Old, L. J., et al. (2023) · doi:10.1158/1078-0432.c.6519084
Yu, P., Steel, J. C., Zhang, M., Morris, J. C., & Waldmann, T. A. (2023) · doi:10.1158/1078-0432.c.6519158
Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Gnjatic, S., Altorki, N. K., Tang, D. N., Tu, S., Kundra, V., Ritter, G., Old, L. J., Logothetis, C. J., & Sharma, P. (2023) · doi:10.1158/1078-0432.c.6517543.v1
Carthon, B. C., Wolchok, J. D., Yuan, J. D., Kamat, A. M., Tang, D. S. N., Sun, J., Ku, G. Y., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2023) · doi:10.1158/1078-0432.c.6519599.v1
Kato, T., Okada, R., Furusawa, A., Inagaki, F. F., Wakiyama, H., Furumoto, H., Okuyama, S., Fukushima, H., Choyke, P. L., & Kobayashi, H. (2023) · doi:10.1158/1535-7163.c.6542778
Kato, T., Okada, R., Furusawa, A., Inagaki, F. F., Wakiyama, H., Furumoto, H., Okuyama, S., Fukushima, H., Choyke, P. L., & Kobayashi, H. (2023) · doi:10.1158/1535-7163.22520790
Martino, M. D., Daviaud, C., Diamond, J. M., Kraynak, J., Alard, A., Formenti, S. C., Miller, L. D., Demaria, S., & Vanpouille‐Box, C. (2023) · doi:10.1158/2326-6066.c.6550333
Data from mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA
Diken, M., Kreiter, S., Vascotto, F., Selmi, A., Attig, S., Diekmann, J., Huber, C., Türeci, Ö., & Şahin, U. (2023) · doi:10.1158/2326-6066.c.6548213.v1
Martino, M. D., Daviaud, C., Diamond, J. M., Kraynak, J., Alard, A., Formenti, S. C., Miller, L. D., Demaria, S., & Vanpouille‐Box, C. (2023) · doi:10.1158/2326-6066.c.6550333.v1
Macrophages – Controlling the Bifurcation Between Tumor Existence or Regression
Novobrantseva, T. I., Manfra, D. J., Nguyen, A., & Feldman, I. (2023) · Advanced Biology · doi:10.1002/adbi.202300047
Potential of Biotechnology in Cancer Management
George, A., Varghese, J., & Padinharayil, H. (2023) · Springer eBooks · doi:10.1007/978-981-99-5281-6_2
Dendritic Cells and Tumor Immunotherapy
Liu, L., Hu, Z., Long, J., Shang, G., & Zeng, Z. (2024) · Springer eBooks · doi:10.1007/978-981-97-6246-0_8
Therapeutic vaccine: A novel immunological approach
Shyamsundar, K. A., Patil, S. S., Rathnamma, D., Suresh, K. P., Ranganatha, S., Manjunatha, J., & Akshatha, V. (2024) · Indian Journal of Comparative Microbiology Immunology and Infectious Diseases · doi:10.5958/0974-0147.2024.00009.6
Introduction on Immune Checkpoints in Cancer
Balibegloo, M., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_158
Exploitation of costimulatory SA-4-1BBL in the development of therapeutic cancer vaccines.
Srivastava, A. (2011) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/1367
Role of Interleukin 21 in CD4 T cell regulation
Attridge, K. (2012) · University of Birmingham Institutional Research Archive (University of Birmingham)
Pre-Existing Immunity Shapes Cancer Immunotherapy Efficacy
Xagara, A., Koinis, F., Tsapakidis, K., Samaras, I., Chantzara, E., Vasilieva, K., Lazarou, A., Georgoulias, V., & Kotsakis, A. P. (2026) · Onco · doi:10.3390/onco6010004
“Moreover, an improved clinical outcome was observed following blockade of PD-1 [96,97], CTLA-4 [98,99], or LAG-3 [100] after vaccination.”
From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma
Mokos, M., & Šitum, M. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16030147
Simonetta, F. (2011) · theses.fr (ABES) · doi:10.70675/032c421dzd23ez4b4aza677z79cae2e44063
Translating IL-2/anti-IL-2 antibody complexes treatment for human tumor immunotherapy
Caudana, P. (2018) · theses.fr (ABES) · doi:10.70675/8a93b17bz416az4e49z9a3bz92c1c8a4cf8c
Champiat, S. (2019) · theses.fr (ABES) · doi:10.70675/e358773dz1898z4feezbb3bzbdee7c7f20a6
Cancer immunotherapy : efficacy and safety of a melanin-based vaccine
Cuzzubbo, S. (2021) · theses.fr (ABES) · doi:10.70675/2e1d38a6z8d99z458dza769zb7bccda2b709
Wierz, M. (2020) · theses.fr (ABES) · doi:10.70675/80454a47z3b6bz4b8bza0c3z684d69f087b3 · Cited by 1
Modulation de l'activation des lymphocytes T et des réponses anti-tumorales par le fer
Porte, S. (2022) · theses.fr (ABES) · doi:10.70675/4251e200zd50ez4a76zb869zb97fa8d3e879
Peroceschi, R. (2024) · theses.fr (ABES) · doi:10.70675/1253a351z345ez4a59za033z3f19256baba1
Chen, J. F., Ding, Z., Lai, S., Gan, Z., Wang, W., Jiao, B., & Yu, Q. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124335
T cell activation and TCRs as an immunotherapeutic approach in cancer
Güney-Kalkan, S. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100450
Breast-specific regulatory T cell mediators
Modanwal, S., Mishra, A., Mishra, N., & Sethi, G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43846-2.00003-9
Encapsulated cell therapy for local anti-CTLA-4 delivery in cancer immunotherapy
Engel, A., Vernet, R., Charrier, E., Urwyler, M., Rohr, O. V., Saingier, V., Courtout, F., Abukscem, S., Bouvarel, T., Lathuilière, A., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116938
“37 We compared the Treg levels in the lymph nodes between all the groups.”
Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance
Oldham, R. J., Mårtensson, L., Semmrich, M., Yoosuf, N., Holmkvist, P., Graham, L. V., Taylor, M. C., Cleary, K. L. S., Yazdani, M., Buckingham, J. F., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03785-5
Destabilization of intratumor Tregs by CTLA-4 engagement confers anti-CTLA-4-driven immunotherapyPreprint
Liu, N., Xu, J., Ku, W. L., Chen, W., Cao, Y., Kazmi, R., Jin, W., Gauthier, T., Luo, S., Shen, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.28.741328
Sambucci, M., Fenoglio, D., Ferrera, F., Camporesi, L., Lagazio, A., Borsellino, G., Battistini, L., & Filaci, G. (2026) · European Journal of Immunology · doi:10.1002/eji.70288
Ionic liquid–mediated cellular loading for whole tumor cell vaccines
Rodrigues, D., Mukherji, M., Park, K. S., Joshi, M., Kapsalis, L., Shaha, S., Bibbey, M. G., Erdi, M., & Mitragotri, S. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2604066123
Biodegradable microparticles for in situ immunization against cancer
Makkouk, A., Norian, L. A., Monick, M., Weiner, G. J., Lubaroff, D., & Salem, A. (2014) · doi:10.17077/etd.sl8jfuqu
“In another B16 melanoma study that combined GVAX ® with anti-CTLA-4, the combination induced greater infiltration and a striking change in the intratumoral balance of effector T cells and Tregs that directly correlated with tumor rejection [109].”
Background
Metadata
- Authors
- Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Quezada, S. A.
- ORCID
- Quezada, S. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1935-1945
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1479425
- OpenAlex
- W2131874142
- Cited by
- 700
- References
- 50
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 22 · 2023: 37 · 2022: 31 · 2021: 44 · 2020: 35 · 2019: 37 · 2018: 41 · 2017: 46 · 2016: 29 · 2015: 41 · 2014: 41 · 2013: 39 · 2012: 38
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, GM-CSF, GVAX, tumor cell vaccine, regulatory T cells, effector T cells, B16-BL6 melanoma, antitumor immunity, Foxp3, CD8+ T cells, CD4+ T cells, tumor rejection, combination immunotherapy
- MeSH terms
- Animals, Antigens, Differentiation, Immunotherapy, Lymph Nodes, Melanoma, Experimental, Mice, Inbred C57BL, Antigens, CD, CD4 Antigens, T-Lymphocyte Subsets, Granulocyte-Macrophage Colony-Stimulating Factor, CD8 Antigens, Cancer Vaccines, Cell Line, Tumor, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.